Publication date: Jun 30, 2020
Preliminary data indicate extensive and rapid absorption of OX125 across all formulations Positive results underline the applicability of Orexo’s novel intranasal drug delivery platform UPPSALA, Sweden, June 30, 2020 /PRNewswire/ — Orexo AB (publ. )
The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorption from three development formulations of OX125, Orexo’s wholly-owned nasal nalmefene product, compared to a nalmefene intramuscular injection.
Preliminary results indicate extensive and rapid absorption across all three OX125 formulations as well as good tolerability, supporting the viability of OX125 as a rescue medication for opioid overdose.
Highly potent synthetic opioids, such as fentanyl, have become the leading cause of death following drug overdoses in the US with over 31,000 fatalities in 2018. 1 Like naloxone, nalmefene is an opioid antagonist that acts by blocking the effects of opioids at the opioid receptors.
The addressable market for OX125 and OX124 is large and growing as demand for easy to use, potent overdose reversal medication increases, not only for emergency staff and first responders, but also for opioid dependent patients, and as co-prescription for high-dose opioid pain patients.
The main market today is the American market for buprenorphine/naloxone products, where Orexo commercialize its lead product Zubsolv(R) for treatment of opioid use disorder.
About OX125 OX125 is a nasal nalmefene rescue medication under development by Orexo.
Naloxone is a full opioid receptor antagonist which reverses the effects of opioid agonists, including the life threatening respiratory depressant effects occurring in an opioid overdose.
|disease||MESH||cause of death|
|disease||MESH||substance use disorders|